DalCor Pharmaceuticals

DalCor Pharmaceuticals, established in 2015, is a biopharmaceutical company specializing in precision medicine for cardiovascular diseases. Headquartered in Sarasota, Florida, with additional offices in Montreal, Zug, and Leatherhead, the company develops targeted treatments based on patients' genetic profiles. Its lead product, dalcetrapib, a cholesterol ester transfer protein inhibitor, is designed to reduce cardiovascular events in patients with acute coronary syndrome who carry a specific ADCY9 genetic marker, as demonstrated in a pharmacogenomics analysis of the dal-Outcomes study. DalCor holds a worldwide exclusive license for dalcetrapib and the ADCY9 genetic marker from Roche.